RestorGenex Corp  

(Public, OTCMKTS:RESX)   Watch this stock  
Find more results for B. Blech
2.99
+0.09 (3.10%)
Feb 27 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range 2.80 - 3.00
52 week 2.37 - 10.20
Open 3.00
Vol / Avg. 9,777.00/4,411.00
Mkt cap 55.68M
P/E     -
Div/yield     -
EPS -1.07
Shares 18.62M
Beta 0.50
Inst. own 0%
Feb 10, 2015
RestorGenex Corp at Biotechnology Industry Organization CEO & Investor Conference
Jan 13, 2015
RestorGenex Corp at EBD Biotech Showcase
  

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin - -3429.54%
Operating margin - -18023.34%
EBITD margin - -10096.50%
Return on average assets -26.33% -23.65%
Return on average equity -31.41% -
CDP Score - -

Address

2150 E Lake Cook Rd Ste 750
BUFFALO GROVE, IL 60089-8227
United States - Map
+1-805-2291829 (Phone)
+1-213-9956337 (Fax)

Website links

Description

RestorGenex Corporation. is a specialty biopharmaceutical company initially focused on developing products for dermatology, ophthalmology and women�s health. The Company�s proposed product portfolio includes a cosmeceutical product line. The Company is engaged in product development for both the cosmeceutical market, as well as the prescription dermatology market. The Company�s HYG-102, a soft estrogen, for the treatment of aging skin fragility/thinning; HYG-440, a soft anti-androgen, for the treatment of androgen excess, e.g. acne, male-pattern baldness; P529, for the treatment of keloid scarring, psoriasis, atopic dermatitis, rosacea, actinic keratosis, Dupuytren�s disease and the bullous blistering diseases; HYG-102, is for vulvar and vaginal atrophy (VVA); HYG-102 and HYG-440 target hormonal aging in women which radically affects the mucous membranes.

Officers and directors

Sol J. Barer Chairman of the Board
Age: 67
Stephen M. Simes Chief Executive Officer, Director
Age: 62
Isaac Blech Vice Chairman of the Board
Age: 64
Phillip B. Donenberg Chief Financial Officer, Secretary
Age: 53
Yael Schwartz Ph.D. President of Canterbury Laboratories LLC, and Hygeia Therapeutics, Inc., Director
Age: 65
Mark Weinberg M.D. Senior Vice President - Clinical Development
David Sherris M.D., Ph.D. Chief Scientific Officer, President - Paloma/VasculoMedics Divisions, Director
Age: 61
Craig Abolin Vice President - Research and Development of Canterbury Laboratories LLC, and Hygeia Therapeutics, Inc.
Age: 66
Rex Bright Director
Age: 74
Nelson K. Stacks Director
Age: 43